Form 8-K - Current report:
SEC Accession No. 0000950170-24-134970
Filing Date
2024-12-10
Accepted
2024-12-10 16:10:05
Documents
17
Period of Report
2024-12-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20241210.htm   iXBRL 8-K 46668
2 EX-1.1 crdf-ex1_1.htm EX-1.1 458809
3 EX-5.1 crdf-ex5_1.htm EX-5.1 35164
4 EX-99.1 crdf-ex99_1.htm EX-99.1 27481
5 GRAPHIC img186708884_0.jpg GRAPHIC 6811
6 GRAPHIC img229051243_0.jpg GRAPHIC 34763
7 GRAPHIC img229051243_1.jpg GRAPHIC 34763
  Complete submission text file 0000950170-24-134970.txt   862969

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crdf-20241210.xsd EX-101.SCH 23903
19 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20241210_htm.xml XML 4500
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 241538572
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)